← Research library

Clinical efficacy and safety of Picamilon in patients with progressive chronic cerebral ischemia

Observational study · 2024

What was studied
50 stage II patients (5 men, 45 women); 70-day active treatment and 45-day follow-up
Main finding
In an uncontrolled 50-person stage II cohort, cognition and sleep questionnaire scores improved during treatment and follow-up.

MoCA cognitive score · 20.9 → 24.6 → 25.9 points · Baseline → end of treatment → delayed follow-up · p<0.0001 and p=0.0006 as reported

Reported findings and study design

In an uncontrolled 50-person stage II cohort, cognition and sleep questionnaire scores improved during treatment and follow-up.

50 patients; 10 days intravenous treatment followed by 60 days oral treatment; final follow-up 1.5 months later.

Population or model 50 stage II patients (5 men, 45 women); 70-day active treatment and 45-day follow-up

Results · Original publisher abstract and selected HTML results checked; patient-series overlap remains unresolved
MeasureResultComparison, timing and statistics
MoCA cognitive score20.9 → 24.6 → 25.9 pointsBaseline → end of treatment → delayed follow-up · p<0.0001 and p=0.0006 as reported
Sleep normalization55% → 81%End of treatment → delayed follow-up; questionnaire-defined · p<0.0001 and p=0.0025
Fedin neurological score17.4 ± 9.34 → 8.06 ± 6.84 → 5.31 ± 5.71 pointsBaseline → visit 2 → visit 3 · p<0.0001 and p=0.0002
Neurological improvement84%Within treated cohort
Autonomic findings38% normalized; 60% had reduced symptom severitySeparate response categories · p=0.0001 as reported
Reported tolerability98%Uncontrolled cohort; not a placebo safety comparison

No untreated comparator was included. Questionnaire sleep changes do not describe deep or REM sleep. Clinical-event prevention is not established by these scale and vascular-marker changes.

Source for these results ↗ · Reviewed 2026-11-01

Study limitations and source details

Study limitations

  • Uncontrolled treatment cohort; expectation, repeated testing and concomitant care can affect outcomes.
  • Questionnaire improvement is not evidence about wearable sleep stages.
  • Strong similarities to the 2025 stage II group warrant overlap checks before any pooling.

Related publications may describe some of the same participants or experiments.

Source details

Publisher HTML article

Original publisher abstract and selected HTML results checked; patient-series overlap remains unresolved

Sources checked

Citation

Uncontrolled human reportFull text available

Danilov AB, Shindryaeva NN, Borodulina IV, Lunegov TD, Kristeleva DA. Clinical efficacy and safety of Picamilon in patients with progressive chronic cerebral ischemia Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova 124(8). PMID 39269299

Study source ↗ · DOI 10.17116/jnevro202412408171 · Bibliography entry · Link to this summary

Related compounds

Editorial policy and evidence standards